Ansa Biotechnologies is a DNA synthesis company based in Emeryville, CA that focuses on producing sequence-perfect clonal DNA and sequence-verified linear double-stranded DNA fragments. Its platform aims to give scientists rapid, accurate access to synthetic DNA for applications across healthcare, life sciences, and other industries. To reinforce reliability, the company recently launched the Ansa On-Time Guarantee, promising that any order not shipped in full and on time will be provided free of charge. It has also rolled out a new pricing framework targeting low-complexity DNA sequences to make routine orders more cost-effective. With its latest capital infusion, Ansa plans to expand U.S. manufacturing capacity, deepen customer-experience initiatives, and strengthen strategic partnerships while advancing its technology stack. Although no revenue or user figures were disclosed, the firm’s continued fundraising indicates growing market traction and operational scaling needs.

Total raised

$130M

Funding rounds

3

Latest round

Series B

Latest activity

Oct 2025